A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma (Q63874514)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 October 2009

edit

Language	Label	Description	Also known as
English	A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma	scientific article published on 15 October 2009

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

title

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

author

Wolfram Samlowski

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

author name string

John Ward

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

Joseph Catlett

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

Lee Cranmer

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

John Kirkwood

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

David Lawson

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

Eric Whitman

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

Rene Gonzalez

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

Karl D Lewis

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

publication date

15 October 2009

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

published in

Investigational New Drugs

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

volume

29

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

issue

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

page(s)

161-166

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

cites work

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survivin, cancer networks and pathway-directed drug discovery.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exploiting the apoptotic route for cancer treatment: a single hit will rarely result in a home run

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Apoptosis and melanoma chemoresistance

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cancer statistics, 2008

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protective role of the inhibitor of apoptosis protein, survivin, in toxin-induced acute renal failure

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19830389

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S10637-009-9333-6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

Dimensions Publication ID

1004560803

0 references

PubMed publication ID

19830389

1 reference

stated in

Europe PubMed Central

PubMed publication ID

19830389

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19830389%20AND%20SRC:MED&resulttype=core&format=json

retrieved

9 February 2020

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q63874514&oldid=2217751672"